ADPT Adaptive Biotechnologies
- 5.940
- +0.210+3.66%
- 5.850
- -0.090-1.52%
Adaptive Biotechnologies News
Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared?
Morgan Stanley Maintains Adaptive Biotechnologies(ADPT.US) With Hold Rating, Maintains Target Price $7
Balanced Hold Recommendation for Adaptive Biotechnologies Amid Positive Performance and External Challenges
Life Sciences Stocks Viewed Positively at TD Cowen Despite Post-election Weakness
Scotiabank Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Maintains Target Price $10
Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) 31% Jump Shows Its Popularity With Investors
Adaptive Biotechnologies Is Maintained at Overweight by Piper Sandler
Piper Sandler Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Raises Target Price to $7
J.P. Morgan Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Raises Target Price to $7
Express News | Adaptive Biotechnologies Corp : Piper Sandler Raises Target Price to $7 From $6
Q3 2024 Adaptive Biotechnologies Corp Earnings Call
TD Cowen Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating
TD Cowen Reaffirms Their Buy Rating on Adaptive Biotechnologies (ADPT)
Adaptive Biotechnologies Corporation (ADPT) Q3 2024 Earnings Call Transcript Summary
Express News | Adaptive Biotechnologies Raises FY2024 Sales Guidance From $140.00M-145.00M to $143.00M-145.00M
Adaptive Biotechnologies Q3 Loss Decreases, Beats Estimates
Adaptive Biotechnologies | 10-Q: Q3 2024 Earnings Report
Adaptive Biotechnologies | 8-K: Adaptive Biotechnologies Reports Third Quarter 2024 Financial Results
Earnings Flash (ADPT) ADAPTIVE BIOTECHNOLOGIES Reports Q3 Revenue $46.4M
Express News | Adaptive Biotechnologies Reports Third Quarter 2024 Financial Results
Analysis
Price Target
No Data
No Data